In class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma - Supplementary Material
收藏数据链接：
官方服务：
资源简介：
Supplementary Figure S1. Study design and timelinesSupplementary Figure S2. Populations for the IRd and V-based cohorts Selected from US MM-6 and INSIGHT MM.Supplementary Table S1. Patient baseline and disease characteristics before IPTW.Supplementary Table S2. Duration of treatment with individual agents in the IRd and V-based IPTW-weighted cohorts.Supplementary Table S3. Stem cell transplant and subsequent PI therapy in the V-based IPTW-weighted cohort.<br>
提供机构：
Taylor & Francis创建时间：
2023-10-09
